nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—ABCB1—esophageal cancer	0.564	1	CbGaD
Amantadine—SLC22A2—Cisplatin—esophageal cancer	0.0764	0.695	CbGbCtD
Amantadine—ABCB1—Cisplatin—esophageal cancer	0.0203	0.185	CbGbCtD
Amantadine—ABCB1—Methotrexate—esophageal cancer	0.0132	0.12	CbGbCtD
Amantadine—Punctate keratitis—Capecitabine—esophageal cancer	0.00531	0.043	CcSEcCtD
Amantadine—Slurred speech—Cisplatin—esophageal cancer	0.00407	0.033	CcSEcCtD
Amantadine—Visual acuity reduced—Capecitabine—esophageal cancer	0.00226	0.0183	CcSEcCtD
Amantadine—Keratitis—Capecitabine—esophageal cancer	0.00207	0.0167	CcSEcCtD
Amantadine—Dysarthria—Cisplatin—esophageal cancer	0.00192	0.0156	CcSEcCtD
Amantadine—Body temperature increased—Carboplatin—esophageal cancer	0.00175	0.0142	CcSEcCtD
Amantadine—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00146	0.0118	CcSEcCtD
Amantadine—Paralysis—Methotrexate—esophageal cancer	0.00144	0.0116	CcSEcCtD
Amantadine—Renal failure acute—Cisplatin—esophageal cancer	0.00143	0.0116	CcSEcCtD
Amantadine—Dysarthria—Capecitabine—esophageal cancer	0.00142	0.0115	CcSEcCtD
Amantadine—Amnesia—Cisplatin—esophageal cancer	0.00141	0.0114	CcSEcCtD
Amantadine—Gait disturbance—Capecitabine—esophageal cancer	0.00137	0.0111	CcSEcCtD
Amantadine—Stupor—Methotrexate—esophageal cancer	0.00134	0.0108	CcSEcCtD
Amantadine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.0013	0.0105	CcSEcCtD
Amantadine—Urinary incontinence—Capecitabine—esophageal cancer	0.0013	0.0105	CcSEcCtD
Amantadine—Irritability—Cisplatin—esophageal cancer	0.00126	0.0102	CcSEcCtD
Amantadine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00121	0.00977	CcSEcCtD
Amantadine—Mental disability—Capecitabine—esophageal cancer	0.00116	0.00943	CcSEcCtD
Amantadine—Sweating increased—Cisplatin—esophageal cancer	0.00111	0.009	CcSEcCtD
Amantadine—Photosensitivity—Capecitabine—esophageal cancer	0.00111	0.00898	CcSEcCtD
Amantadine—Dysarthria—Methotrexate—esophageal cancer	0.00106	0.00855	CcSEcCtD
Amantadine—Renal failure acute—Capecitabine—esophageal cancer	0.00105	0.00854	CcSEcCtD
Amantadine—Libido decreased—Capecitabine—esophageal cancer	0.00105	0.0085	CcSEcCtD
Amantadine—Amnesia—Capecitabine—esophageal cancer	0.00104	0.00839	CcSEcCtD
Amantadine—Cardiac failure—Capecitabine—esophageal cancer	0.000998	0.00808	CcSEcCtD
Amantadine—Lethargy—Capecitabine—esophageal cancer	0.000994	0.00805	CcSEcCtD
Amantadine—Osteoarthritis—Capecitabine—esophageal cancer	0.000974	0.00788	CcSEcCtD
Amantadine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000966	0.00782	CcSEcCtD
Amantadine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000964	0.00781	CcSEcCtD
Amantadine—Irritability—Capecitabine—esophageal cancer	0.000929	0.00753	CcSEcCtD
Amantadine—Cardiac arrest—Capecitabine—esophageal cancer	0.000926	0.0075	CcSEcCtD
Amantadine—Urinary retention—Capecitabine—esophageal cancer	0.000926	0.0075	CcSEcCtD
Amantadine—Ataxia—Capecitabine—esophageal cancer	0.000916	0.00741	CcSEcCtD
Amantadine—Coma—Methotrexate—esophageal cancer	0.000912	0.00739	CcSEcCtD
Amantadine—Urinary tract disorder—Cisplatin—esophageal cancer	0.000902	0.00731	CcSEcCtD
Amantadine—Liver function test abnormal—Capecitabine—esophageal cancer	0.000899	0.00728	CcSEcCtD
Amantadine—Urethral disorder—Cisplatin—esophageal cancer	0.000896	0.00725	CcSEcCtD
Amantadine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000889	0.0072	CcSEcCtD
Amantadine—Pulmonary oedema—Methotrexate—esophageal cancer	0.000889	0.0072	CcSEcCtD
Amantadine—Visual impairment—Cisplatin—esophageal cancer	0.000881	0.00713	CcSEcCtD
Amantadine—Eye disorder—Cisplatin—esophageal cancer	0.000854	0.00691	CcSEcCtD
Amantadine—Cardiac disorder—Cisplatin—esophageal cancer	0.000848	0.00687	CcSEcCtD
Amantadine—Dysphagia—Capecitabine—esophageal cancer	0.000842	0.00681	CcSEcCtD
Amantadine—Photosensitivity—Methotrexate—esophageal cancer	0.000825	0.00668	CcSEcCtD
Amantadine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000824	0.00667	CcSEcCtD
Amantadine—Sweating increased—Capecitabine—esophageal cancer	0.00082	0.00664	CcSEcCtD
Amantadine—Arrhythmia—Cisplatin—esophageal cancer	0.000816	0.00661	CcSEcCtD
Amantadine—Alopecia—Cisplatin—esophageal cancer	0.000807	0.00654	CcSEcCtD
Amantadine—Malnutrition—Cisplatin—esophageal cancer	0.000795	0.00644	CcSEcCtD
Amantadine—Neutropenia—Capecitabine—esophageal cancer	0.000787	0.00637	CcSEcCtD
Amantadine—Renal failure acute—Methotrexate—esophageal cancer	0.000785	0.00636	CcSEcCtD
Amantadine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000768	0.00622	CcSEcCtD
Amantadine—Visual disturbance—Methotrexate—esophageal cancer	0.000765	0.00619	CcSEcCtD
Amantadine—Vision blurred—Cisplatin—esophageal cancer	0.00075	0.00607	CcSEcCtD
Amantadine—Tremor—Cisplatin—esophageal cancer	0.000745	0.00603	CcSEcCtD
Amantadine—Lethargy—Methotrexate—esophageal cancer	0.00074	0.00599	CcSEcCtD
Amantadine—Osteoarthritis—Methotrexate—esophageal cancer	0.000725	0.00587	CcSEcCtD
Amantadine—Leukopenia—Cisplatin—esophageal cancer	0.000712	0.00577	CcSEcCtD
Amantadine—Agranulocytosis—Capecitabine—esophageal cancer	0.0007	0.00567	CcSEcCtD
Amantadine—Irritability—Methotrexate—esophageal cancer	0.000692	0.0056	CcSEcCtD
Amantadine—Convulsion—Cisplatin—esophageal cancer	0.000689	0.00558	CcSEcCtD
Amantadine—Ataxia—Methotrexate—esophageal cancer	0.000682	0.00552	CcSEcCtD
Amantadine—Anxiety—Cisplatin—esophageal cancer	0.000675	0.00546	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000673	0.00545	CcSEcCtD
Amantadine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000669	0.00542	CcSEcCtD
Amantadine—Urinary tract disorder—Capecitabine—esophageal cancer	0.000665	0.00539	CcSEcCtD
Amantadine—Oedema peripheral—Capecitabine—esophageal cancer	0.000664	0.00537	CcSEcCtD
Amantadine—Urethral disorder—Capecitabine—esophageal cancer	0.00066	0.00535	CcSEcCtD
Amantadine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000649	0.00526	CcSEcCtD
Amantadine—Oedema—Cisplatin—esophageal cancer	0.000649	0.00526	CcSEcCtD
Amantadine—Visual impairment—Capecitabine—esophageal cancer	0.000649	0.00526	CcSEcCtD
Amantadine—Nervous system disorder—Cisplatin—esophageal cancer	0.000637	0.00516	CcSEcCtD
Amantadine—Tachycardia—Cisplatin—esophageal cancer	0.000634	0.00513	CcSEcCtD
Amantadine—Skin disorder—Cisplatin—esophageal cancer	0.000631	0.00511	CcSEcCtD
Amantadine—Eye disorder—Capecitabine—esophageal cancer	0.000629	0.0051	CcSEcCtD
Amantadine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000628	0.00508	CcSEcCtD
Amantadine—Cardiac disorder—Capecitabine—esophageal cancer	0.000625	0.00506	CcSEcCtD
Amantadine—Anorexia—Cisplatin—esophageal cancer	0.000619	0.00501	CcSEcCtD
Amantadine—Angiopathy—Capecitabine—esophageal cancer	0.000611	0.00495	CcSEcCtD
Amantadine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000607	0.00492	CcSEcCtD
Amantadine—Hypotension—Cisplatin—esophageal cancer	0.000607	0.00491	CcSEcCtD
Amantadine—Arrhythmia—Capecitabine—esophageal cancer	0.000602	0.00487	CcSEcCtD
Amantadine—Alopecia—Capecitabine—esophageal cancer	0.000595	0.00482	CcSEcCtD
Amantadine—Mental disorder—Capecitabine—esophageal cancer	0.00059	0.00478	CcSEcCtD
Amantadine—Malnutrition—Capecitabine—esophageal cancer	0.000586	0.00475	CcSEcCtD
Amantadine—Neutropenia—Methotrexate—esophageal cancer	0.000586	0.00474	CcSEcCtD
Amantadine—Paraesthesia—Cisplatin—esophageal cancer	0.000583	0.00472	CcSEcCtD
Amantadine—Dyspnoea—Cisplatin—esophageal cancer	0.000579	0.00469	CcSEcCtD
Amantadine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000572	0.00463	CcSEcCtD
Amantadine—Decreased appetite—Cisplatin—esophageal cancer	0.000564	0.00457	CcSEcCtD
Amantadine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00056	0.00454	CcSEcCtD
Amantadine—Vision blurred—Capecitabine—esophageal cancer	0.000553	0.00447	CcSEcCtD
Amantadine—Tremor—Capecitabine—esophageal cancer	0.000549	0.00445	CcSEcCtD
Amantadine—Feeling abnormal—Cisplatin—esophageal cancer	0.000535	0.00433	CcSEcCtD
Amantadine—Leukopenia—Capecitabine—esophageal cancer	0.000525	0.00425	CcSEcCtD
Amantadine—Agranulocytosis—Methotrexate—esophageal cancer	0.000521	0.00422	CcSEcCtD
Amantadine—Palpitations—Capecitabine—esophageal cancer	0.000518	0.0042	CcSEcCtD
Amantadine—Body temperature increased—Cisplatin—esophageal cancer	0.000513	0.00416	CcSEcCtD
Amantadine—Hypertension—Capecitabine—esophageal cancer	0.000506	0.0041	CcSEcCtD
Amantadine—Anxiety—Capecitabine—esophageal cancer	0.000497	0.00403	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000496	0.00401	CcSEcCtD
Amantadine—Urinary tract disorder—Methotrexate—esophageal cancer	0.000495	0.00401	CcSEcCtD
Amantadine—Urethral disorder—Methotrexate—esophageal cancer	0.000492	0.00398	CcSEcCtD
Amantadine—Dry mouth—Capecitabine—esophageal cancer	0.000488	0.00395	CcSEcCtD
Amantadine—Visual impairment—Methotrexate—esophageal cancer	0.000483	0.00391	CcSEcCtD
Amantadine—Confusional state—Capecitabine—esophageal cancer	0.000483	0.00391	CcSEcCtD
Amantadine—Oedema—Capecitabine—esophageal cancer	0.000479	0.00388	CcSEcCtD
Amantadine—Hypersensitivity—Cisplatin—esophageal cancer	0.000478	0.00387	CcSEcCtD
Amantadine—Nervous system disorder—Capecitabine—esophageal cancer	0.000469	0.0038	CcSEcCtD
Amantadine—Eye disorder—Methotrexate—esophageal cancer	0.000469	0.00379	CcSEcCtD
Amantadine—Tachycardia—Capecitabine—esophageal cancer	0.000467	0.00378	CcSEcCtD
Amantadine—Asthenia—Cisplatin—esophageal cancer	0.000466	0.00377	CcSEcCtD
Amantadine—Cardiac disorder—Methotrexate—esophageal cancer	0.000465	0.00377	CcSEcCtD
Amantadine—Skin disorder—Capecitabine—esophageal cancer	0.000465	0.00376	CcSEcCtD
Amantadine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000463	0.00375	CcSEcCtD
Amantadine—Anorexia—Capecitabine—esophageal cancer	0.000456	0.00369	CcSEcCtD
Amantadine—Angiopathy—Methotrexate—esophageal cancer	0.000455	0.00368	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000452	0.00366	CcSEcCtD
Amantadine—Hypotension—Capecitabine—esophageal cancer	0.000447	0.00362	CcSEcCtD
Amantadine—Diarrhoea—Cisplatin—esophageal cancer	0.000444	0.0036	CcSEcCtD
Amantadine—Alopecia—Methotrexate—esophageal cancer	0.000443	0.00359	CcSEcCtD
Amantadine—Mental disorder—Methotrexate—esophageal cancer	0.000439	0.00356	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—esophageal cancer	0.000436	0.00353	CcSEcCtD
Amantadine—Insomnia—Capecitabine—esophageal cancer	0.000433	0.0035	CcSEcCtD
Amantadine—Paraesthesia—Capecitabine—esophageal cancer	0.00043	0.00348	CcSEcCtD
Amantadine—Dyspnoea—Capecitabine—esophageal cancer	0.000427	0.00345	CcSEcCtD
Amantadine—Dyspepsia—Capecitabine—esophageal cancer	0.000421	0.00341	CcSEcCtD
Amantadine—Decreased appetite—Capecitabine—esophageal cancer	0.000416	0.00337	CcSEcCtD
Amantadine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000413	0.00335	CcSEcCtD
Amantadine—Vomiting—Cisplatin—esophageal cancer	0.000413	0.00334	CcSEcCtD
Amantadine—Fatigue—Capecitabine—esophageal cancer	0.000413	0.00334	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—esophageal cancer	0.000411	0.00333	CcSEcCtD
Amantadine—Rash—Cisplatin—esophageal cancer	0.000409	0.00331	CcSEcCtD
Amantadine—Constipation—Capecitabine—esophageal cancer	0.000409	0.00331	CcSEcCtD
Amantadine—Dermatitis—Cisplatin—esophageal cancer	0.000409	0.00331	CcSEcCtD
Amantadine—Feeling abnormal—Capecitabine—esophageal cancer	0.000394	0.00319	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—esophageal cancer	0.000391	0.00316	CcSEcCtD
Amantadine—Nausea—Cisplatin—esophageal cancer	0.000386	0.00312	CcSEcCtD
Amantadine—Body temperature increased—Capecitabine—esophageal cancer	0.000378	0.00306	CcSEcCtD
Amantadine—Convulsion—Methotrexate—esophageal cancer	0.000378	0.00306	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000369	0.00299	CcSEcCtD
Amantadine—Confusional state—Methotrexate—esophageal cancer	0.000359	0.00291	CcSEcCtD
Amantadine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000356	0.00288	CcSEcCtD
Amantadine—Hypersensitivity—Capecitabine—esophageal cancer	0.000353	0.00285	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—esophageal cancer	0.000349	0.00283	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—esophageal cancer	0.000346	0.0028	CcSEcCtD
Amantadine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000344	0.00279	CcSEcCtD
Amantadine—Asthenia—Capecitabine—esophageal cancer	0.000343	0.00278	CcSEcCtD
Amantadine—Anorexia—Methotrexate—esophageal cancer	0.00034	0.00275	CcSEcCtD
Amantadine—Pruritus—Capecitabine—esophageal cancer	0.000339	0.00274	CcSEcCtD
Amantadine—Hypotension—Methotrexate—esophageal cancer	0.000333	0.0027	CcSEcCtD
Amantadine—Diarrhoea—Capecitabine—esophageal cancer	0.000327	0.00265	CcSEcCtD
Amantadine—Insomnia—Methotrexate—esophageal cancer	0.000322	0.00261	CcSEcCtD
Amantadine—Paraesthesia—Methotrexate—esophageal cancer	0.00032	0.00259	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—esophageal cancer	0.000318	0.00257	CcSEcCtD
Amantadine—Somnolence—Methotrexate—esophageal cancer	0.000317	0.00256	CcSEcCtD
Amantadine—Dizziness—Capecitabine—esophageal cancer	0.000316	0.00256	CcSEcCtD
Amantadine—Dyspepsia—Methotrexate—esophageal cancer	0.000314	0.00254	CcSEcCtD
Amantadine—Decreased appetite—Methotrexate—esophageal cancer	0.00031	0.00251	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000308	0.00249	CcSEcCtD
Amantadine—Fatigue—Methotrexate—esophageal cancer	0.000307	0.00249	CcSEcCtD
Amantadine—Vomiting—Capecitabine—esophageal cancer	0.000304	0.00246	CcSEcCtD
Amantadine—Rash—Capecitabine—esophageal cancer	0.000302	0.00244	CcSEcCtD
Amantadine—Dermatitis—Capecitabine—esophageal cancer	0.000301	0.00244	CcSEcCtD
Amantadine—Headache—Capecitabine—esophageal cancer	0.0003	0.00243	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—esophageal cancer	0.000294	0.00238	CcSEcCtD
Amantadine—Nausea—Capecitabine—esophageal cancer	0.000284	0.0023	CcSEcCtD
Amantadine—Body temperature increased—Methotrexate—esophageal cancer	0.000282	0.00228	CcSEcCtD
Amantadine—Hypersensitivity—Methotrexate—esophageal cancer	0.000262	0.00213	CcSEcCtD
Amantadine—Asthenia—Methotrexate—esophageal cancer	0.000256	0.00207	CcSEcCtD
Amantadine—Pruritus—Methotrexate—esophageal cancer	0.000252	0.00204	CcSEcCtD
Amantadine—Diarrhoea—Methotrexate—esophageal cancer	0.000244	0.00197	CcSEcCtD
Amantadine—Dizziness—Methotrexate—esophageal cancer	0.000236	0.00191	CcSEcCtD
Amantadine—Vomiting—Methotrexate—esophageal cancer	0.000227	0.00183	CcSEcCtD
Amantadine—Rash—Methotrexate—esophageal cancer	0.000225	0.00182	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—esophageal cancer	0.000224	0.00182	CcSEcCtD
Amantadine—Headache—Methotrexate—esophageal cancer	0.000223	0.00181	CcSEcCtD
Amantadine—Nausea—Methotrexate—esophageal cancer	0.000212	0.00171	CcSEcCtD
Amantadine—MAOB—Metabolism—TPI1—esophageal cancer	0.00013	0.00064	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MET—esophageal cancer	0.00013	0.00064	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—ERBB2—esophageal cancer	0.000129	0.000639	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KDR—esophageal cancer	0.000129	0.000638	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL2—esophageal cancer	0.000128	0.000634	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000128	0.000631	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MET—esophageal cancer	0.000126	0.000624	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC52A3—esophageal cancer	0.000126	0.00062	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—BLVRB—esophageal cancer	0.000126	0.00062	CbGpPWpGaD
Amantadine—DDC—Metabolism—ALDH2—esophageal cancer	0.000126	0.00062	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000125	0.000619	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NOTCH1—esophageal cancer	0.000125	0.000616	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000125	0.000615	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ALDOB—esophageal cancer	0.000124	0.000614	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GDI2—esophageal cancer	0.000122	0.000604	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NOTCH1—esophageal cancer	0.000122	0.000601	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	0.000121	0.000598	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GAPDH—esophageal cancer	0.00012	0.000591	CbGpPWpGaD
Amantadine—DDC—Metabolism—GSTT1—esophageal cancer	0.000119	0.00059	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—ANXA1—esophageal cancer	0.000119	0.000589	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000119	0.000588	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—NOS2—esophageal cancer	0.000119	0.000586	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CRABP1—esophageal cancer	0.000119	0.000586	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP2A6—esophageal cancer	0.000118	0.000583	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000117	0.000578	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC52A3—esophageal cancer	0.000117	0.000578	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—BLVRB—esophageal cancer	0.000117	0.000578	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—SST—esophageal cancer	0.000116	0.000573	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CREBBP—esophageal cancer	0.000113	0.000559	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—GHRL—esophageal cancer	0.000113	0.000559	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GNG7—esophageal cancer	0.000113	0.000557	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS1—esophageal cancer	0.000112	0.000553	CbGpPWpGaD
Amantadine—DDC—Metabolism—ENO1—esophageal cancer	0.000112	0.000553	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000111	0.000548	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CREBBP—esophageal cancer	0.00011	0.000545	CbGpPWpGaD
Amantadine—DDC—Metabolism—PSME2—esophageal cancer	0.00011	0.000545	CbGpPWpGaD
Amantadine—DDC—Metabolism—PSME1—esophageal cancer	0.00011	0.000545	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	0.000109	0.000541	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SLC10A2—esophageal cancer	0.000107	0.000527	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CA1—esophageal cancer	0.000107	0.000527	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000106	0.000524	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000106	0.000523	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ALDH2—esophageal cancer	0.000106	0.000522	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000103	0.000508	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000101	0.000501	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000101	0.000501	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GSTT1—esophageal cancer	0.000101	0.000497	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CA1—esophageal cancer	9.95e-05	0.000492	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC10A2—esophageal cancer	9.95e-05	0.000492	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP2A6—esophageal cancer	9.93e-05	0.000491	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CA2—esophageal cancer	9.76e-05	0.000482	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	9.73e-05	0.00048	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP1B1—esophageal cancer	9.51e-05	0.00047	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—ERBB2—esophageal cancer	9.47e-05	0.000468	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKAP13—esophageal cancer	9.46e-05	0.000467	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS1—esophageal cancer	9.42e-05	0.000465	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ENO1—esophageal cancer	9.42e-05	0.000465	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PSME1—esophageal cancer	9.28e-05	0.000459	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PSME2—esophageal cancer	9.28e-05	0.000459	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ERBB2—esophageal cancer	9.23e-05	0.000456	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—EGFR—esophageal cancer	9.2e-05	0.000455	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CA2—esophageal cancer	9.1e-05	0.00045	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PLCE1—esophageal cancer	9.08e-05	0.000448	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ADH7—esophageal cancer	9.08e-05	0.000448	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—EGFR—esophageal cancer	8.97e-05	0.000443	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP19A1—esophageal cancer	8.94e-05	0.000442	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KMT2D—esophageal cancer	8.84e-05	0.000437	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PDE4D—esophageal cancer	8.65e-05	0.000428	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKAP13—esophageal cancer	8.59e-05	0.000425	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ADH7—esophageal cancer	8.46e-05	0.000418	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PLCE1—esophageal cancer	8.46e-05	0.000418	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GNG7—esophageal cancer	8.23e-05	0.000407	CbGpPWpGaD
Amantadine—DDC—Metabolism—HMOX1—esophageal cancer	8.16e-05	0.000403	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP1B1—esophageal cancer	8.01e-05	0.000396	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ADH1B—esophageal cancer	7.96e-05	0.000393	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ADCYAP1—esophageal cancer	7.88e-05	0.000389	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PDE4D—esophageal cancer	7.86e-05	0.000388	CbGpPWpGaD
Amantadine—DDC—Metabolism—ABCB1—esophageal cancer	7.83e-05	0.000387	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	7.78e-05	0.000385	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EP300—esophageal cancer	7.7e-05	0.000381	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	7.69e-05	0.00038	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMP—esophageal cancer	7.61e-05	0.000376	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP19A1—esophageal cancer	7.53e-05	0.000372	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EP300—esophageal cancer	7.51e-05	0.000371	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GNG7—esophageal cancer	7.48e-05	0.000369	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	7.47e-05	0.000369	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ADH1B—esophageal cancer	7.42e-05	0.000366	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP26A1—esophageal cancer	7.4e-05	0.000366	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—EP300—esophageal cancer	7.26e-05	0.000359	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	7.26e-05	0.000358	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL2—esophageal cancer	7.25e-05	0.000358	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALOX15—esophageal cancer	7.21e-05	0.000356	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—WWOX—esophageal cancer	7.2e-05	0.000356	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMP—esophageal cancer	7.09e-05	0.00035	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.98e-05	0.000345	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	6.96e-05	0.000344	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.9e-05	0.000341	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP26A1—esophageal cancer	6.9e-05	0.000341	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTO1—esophageal cancer	6.88e-05	0.00034	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TPI1—esophageal cancer	6.88e-05	0.00034	CbGpPWpGaD
Amantadine—MAOB—Metabolism—HMOX1—esophageal cancer	6.87e-05	0.000339	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.87e-05	0.000339	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BLVRB—esophageal cancer	6.86e-05	0.000339	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC52A3—esophageal cancer	6.86e-05	0.000339	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FKBP1A—esophageal cancer	6.85e-05	0.000339	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—ANXA1—esophageal cancer	6.74e-05	0.000333	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALOX15—esophageal cancer	6.72e-05	0.000332	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—WIF1—esophageal cancer	6.7e-05	0.000331	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALDOB—esophageal cancer	6.59e-05	0.000326	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ABCB1—esophageal cancer	6.59e-05	0.000326	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL2—esophageal cancer	6.59e-05	0.000325	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EGFR—esophageal cancer	6.57e-05	0.000324	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—SST—esophageal cancer	6.56e-05	0.000324	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTO1—esophageal cancer	6.41e-05	0.000317	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TPI1—esophageal cancer	6.41e-05	0.000317	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EGFR—esophageal cancer	6.4e-05	0.000316	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GHRL—esophageal cancer	6.39e-05	0.000316	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GAPDH—esophageal cancer	6.35e-05	0.000314	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CRABP1—esophageal cancer	6.29e-05	0.000311	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CSNK1A1—esophageal cancer	6.18e-05	0.000305	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALDOB—esophageal cancer	6.15e-05	0.000304	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—ANXA1—esophageal cancer	6.12e-05	0.000302	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GNG7—esophageal cancer	5.98e-05	0.000296	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—SST—esophageal cancer	5.96e-05	0.000294	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.92e-05	0.000293	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GAPDH—esophageal cancer	5.92e-05	0.000292	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CRABP1—esophageal cancer	5.86e-05	0.00029	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CA1—esophageal cancer	5.83e-05	0.000288	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC10A2—esophageal cancer	5.83e-05	0.000288	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GHRL—esophageal cancer	5.8e-05	0.000287	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PFN1—esophageal cancer	5.78e-05	0.000286	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.75e-05	0.000284	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	5.63e-05	0.000278	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALDH2—esophageal cancer	5.61e-05	0.000277	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GNG7—esophageal cancer	5.58e-05	0.000276	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CA2—esophageal cancer	5.33e-05	0.000264	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTT1—esophageal cancer	5.33e-05	0.000264	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP2A6—esophageal cancer	5.27e-05	0.00026	CbGpPWpGaD
Amantadine—DDC—Metabolism—CREBBP—esophageal cancer	5.24e-05	0.000259	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALDH2—esophageal cancer	5.23e-05	0.000258	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ELMO1—esophageal cancer	5.19e-05	0.000257	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—esophageal cancer	5.19e-05	0.000257	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	5.08e-05	0.000251	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKAP13—esophageal cancer	5.08e-05	0.000251	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS1—esophageal cancer	5e-05	0.000247	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ENO1—esophageal cancer	5e-05	0.000247	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.99e-05	0.000247	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTT1—esophageal cancer	4.97e-05	0.000246	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ADH7—esophageal cancer	4.96e-05	0.000245	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLCE1—esophageal cancer	4.96e-05	0.000245	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PSME2—esophageal cancer	4.92e-05	0.000243	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PSME1—esophageal cancer	4.92e-05	0.000243	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.92e-05	0.000243	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP2A6—esophageal cancer	4.91e-05	0.000243	CbGpPWpGaD
Amantadine—DDC—Metabolism—NOS3—esophageal cancer	4.69e-05	0.000232	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIST1H2BM—esophageal cancer	4.68e-05	0.000231	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.68e-05	0.000231	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS1—esophageal cancer	4.66e-05	0.00023	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ENO1—esophageal cancer	4.66e-05	0.00023	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	4.65e-05	0.00023	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDE4D—esophageal cancer	4.64e-05	0.000229	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PSME2—esophageal cancer	4.59e-05	0.000227	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PSME1—esophageal cancer	4.59e-05	0.000227	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GNG7—esophageal cancer	4.42e-05	0.000218	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CREBBP—esophageal cancer	4.41e-05	0.000218	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ADH1B—esophageal cancer	4.35e-05	0.000215	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—esophageal cancer	4.29e-05	0.000212	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.25e-05	0.00021	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP1B1—esophageal cancer	4.25e-05	0.00021	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMP—esophageal cancer	4.16e-05	0.000205	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—XIAP—esophageal cancer	4.14e-05	0.000204	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	4.08e-05	0.000201	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP26A1—esophageal cancer	4.04e-05	0.0002	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP19A1—esophageal cancer	4e-05	0.000197	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.99e-05	0.000197	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP1B1—esophageal cancer	3.96e-05	0.000196	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NOS3—esophageal cancer	3.95e-05	0.000195	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALOX15—esophageal cancer	3.94e-05	0.000195	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNA1—esophageal cancer	3.91e-05	0.000193	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL2—esophageal cancer	3.89e-05	0.000192	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTO1—esophageal cancer	3.76e-05	0.000186	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TPI1—esophageal cancer	3.76e-05	0.000186	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP19A1—esophageal cancer	3.72e-05	0.000184	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—HMOX1—esophageal cancer	3.65e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PSME1—esophageal cancer	3.63e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PSME2—esophageal cancer	3.63e-05	0.00018	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ANXA1—esophageal cancer	3.62e-05	0.000179	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—esophageal cancer	3.61e-05	0.000178	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALDOB—esophageal cancer	3.6e-05	0.000178	CbGpPWpGaD
Amantadine—DDC—Metabolism—EP300—esophageal cancer	3.57e-05	0.000176	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SST—esophageal cancer	3.52e-05	0.000174	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ABCB1—esophageal cancer	3.5e-05	0.000173	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GAPDH—esophageal cancer	3.47e-05	0.000171	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.46e-05	0.000171	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CRABP1—esophageal cancer	3.44e-05	0.00017	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH3—esophageal cancer	3.43e-05	0.000169	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GHRL—esophageal cancer	3.43e-05	0.000169	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—HMOX1—esophageal cancer	3.4e-05	0.000168	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FBXW7—esophageal cancer	3.37e-05	0.000167	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.35e-05	0.000165	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNG7—esophageal cancer	3.27e-05	0.000162	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ABCB1—esophageal cancer	3.26e-05	0.000161	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH2—esophageal cancer	3.08e-05	0.000152	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALDH2—esophageal cancer	3.06e-05	0.000151	CbGpPWpGaD
Amantadine—MAOB—Metabolism—EP300—esophageal cancer	3e-05	0.000148	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTT1—esophageal cancer	2.91e-05	0.000144	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.88e-05	0.000142	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ENO1—esophageal cancer	2.73e-05	0.000135	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS1—esophageal cancer	2.73e-05	0.000135	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFBR2—esophageal cancer	2.73e-05	0.000135	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.73e-05	0.000135	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PSME1—esophageal cancer	2.69e-05	0.000133	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PSME2—esophageal cancer	2.69e-05	0.000133	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—esophageal cancer	2.64e-05	0.00013	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SMAD4—esophageal cancer	2.58e-05	0.000128	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CREBBP—esophageal cancer	2.34e-05	0.000116	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.32e-05	0.000115	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—esophageal cancer	2.22e-05	0.00011	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.18e-05	0.000108	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CREBBP—esophageal cancer	2.18e-05	0.000108	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIF1A—esophageal cancer	2.11e-05	0.000104	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NOS3—esophageal cancer	2.09e-05	0.000103	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KDR—esophageal cancer	2.02e-05	9.98e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HMOX1—esophageal cancer	1.99e-05	9.84e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NOS3—esophageal cancer	1.95e-05	9.64e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—esophageal cancer	1.92e-05	9.46e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	1.9e-05	9.4e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—esophageal cancer	1.79e-05	8.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.73e-05	8.53e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.7e-05	8.38e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.62e-05	8.01e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—EP300—esophageal cancer	1.59e-05	7.87e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.55e-05	7.63e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—EP300—esophageal cancer	1.48e-05	7.34e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.47e-05	7.27e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.45e-05	7.14e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CREBBP—esophageal cancer	1.28e-05	6.31e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—esophageal cancer	1.28e-05	6.31e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	1.24e-05	6.1e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—esophageal cancer	1.18e-05	5.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EP300—esophageal cancer	1.18e-05	5.81e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NOS3—esophageal cancer	1.14e-05	5.65e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—esophageal cancer	1.1e-05	5.43e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—esophageal cancer	1.05e-05	5.17e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—esophageal cancer	1.02e-05	5.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—esophageal cancer	1e-05	4.95e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—EP300—esophageal cancer	8.7e-06	4.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	8.7e-06	4.3e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—esophageal cancer	8.41e-06	4.16e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.44e-06	3.18e-05	CbGpPWpGaD
